JPM: Regeneron execs say ‘it’s a problem’ how few COVID-19 patients are getting antibody treatments

To Regeneron, there’s no question about it: “We as a society have to do a much better job” of getting antibody therapies—such as the company’s own—to patients, R&D chief George Yancopoulos said Monday at the J.P. Morgan Healthcare Conference. Like Eli Lilly’s single-antibody treatment, Regeneron’s antibody cocktail bears an emergency use authorization in mild-to-moderate COVID-19 patients at […]

How brain inflammation and healing is pointing to new glioblastoma targets

Canadian researchers have discovered that the healing process after a brain injury can give rise to the deadly brain tumor glioblastoma. By digging further to better understand that phenomenon, they’ve uncovered potential techniques for treating glioblastoma with precision medicine. Researchers from the University of Toronto, Hospital for Sick Children and the Princess Margaret Cancer Centre […]

Issues at Italian CDMO leads to US approval delay for Novartis’ inclisiran

he US FDA has issued a complete response letter for Leqvio (inclisiran) due to ‘unresolved facility inspection-related conditions’ at a third-party site run by Corden Pharma. In October 2020, this publication reported the US approval of Novartis’ small interfering RNA (siRNA) therapy for the treatment of adults with hypercholesterolemia or mixed dyslipidemia, Leqvio, was dependent […]

Covid-19 roundup: Inovio enlists plasmid manufacturer to replace the one it’s in legal feud with; Cyberattacks spotted targeting vaccine distribution 

With its Phase II trial finally underway, Inovio has enlisted another key manufacturing partner to hit its goal of hundreds of millions of doses of its DNA vaccine — filling the role of a contract manufacturer it’s still in a legal standoff with. Japan’s Kaneka Eurogentec is tasked with plasmid production, for which Inovio has […]


December 10, 2020 – An historic alliance of life sciences and healthcare organizations seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The Decentralized Trials & Research Alliance (DTRA) plans to unite stakeholders, including healthcare companies, regulators, patient groups and research organizations, with a mission to make clinical trial participation widely accessible […]

Report Study | Impact of COVID-19 on the Global Rare Neurodegenerative Disease Treatment Market

A new study on the Rare Neurodegenerative Disease Treatment market provides a detailed overview of the demands and consumptions of various products/services associated with the growth dynamics of the market. The in-depth market estimation of various opportunities in the segments is expressed in volumes and revenues during the forecast period 2020 to 2030. The insights and […]


In a large clinical trial, Inmazeb showed superiority compared to other investigational agents (ZMapp and remdesivir) with respect to mortality; treatment was most effective when given early in the course of disease1 Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) is a novel anti-viral antibody medicine developed using the same ‘rapid response’ technologies as Regeneron’s investigational COVID-19 antibody […]